New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.

This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right decisions about which compounds to take forward to avoid cardiovascular toxicity, the leading cause of safety-related project failure in drug development today.

Read more here: New Drug Discovery Alliance to Tackle High Rate of Failure in Drug Development

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.